Edition:
United Kingdom

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

72.28USD
17 Nov 2017
Change (% chg)

$-0.02 (-0.03%)
Prev Close
$72.30
Open
$70.95
Day's High
$72.38
Day's Low
$70.90
Volume
366,441
Avg. Vol
353,669
52-wk High
$75.87
52-wk Low
$37.37

Chart for

About

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-re... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $5,508.56
Shares Outstanding(Mil.): 88.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.24 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-Neurocrine Biosciences reports Q3 loss per share $0.13

* Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S

01 Nov 2017

BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza

* Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome

25 Oct 2017

BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine

* Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome Source text for Eikon: Further company coverage:

23 Oct 2017

BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza

* Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)

05 Oct 2017

BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences

* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​ Source: (http://bit.ly/2wOUVQY) Further company coverage:

08 Sep 2017

BRIEF-Neurocrine Biosciences Q2 loss per share $0.68

* Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S

03 Aug 2017

BRIEF-Neurocrine Biosciences says PDUFA goal date is Oct. 14 for Ingrezza 80 mg capsules

* Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14, 2017 for Ingrezza 80 mg capsules - sec filing Source text for Eikon: (http://bit.ly/2spiVra) Further company coverage:

05 Jul 2017

BRIEF-Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients

* Neurocrine announces phase ii results of vmat2 inhibitor ingrezza® for treatment of tourette syndrome

23 May 2017

Earnings vs. Estimates